An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how common respiratory syncytial virus (RSV) infections are in adults who have received a stem cell transplant or have certain blood cancers, like leukemia or lymphoma, at the Tianjin Hematology Institute. The main goal is to better understand how often these infections occur in this specific group of patients, especially those experiencing new or worsening breathing problems.

To participate in the study, individuals need to be at least 18 years old and either have received a stem cell transplant or are currently undergoing treatment for blood cancers. They must also have new respiratory symptoms or an increase in any existing breathing issues. Participants will need to agree to the study terms and be willing to follow the guidelines. This trial is currently looking for volunteers, and those who join will help researchers learn more about RSV infections in these vulnerable patients, which could improve future care and treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Aged ≥ 18 years old. 2) Receiving hematopoietic stem cell transplantation; OR being diagnosed with hematological malignancies (including but not limited to leukemia, lymphoma, and multiple myeloma) and receiving chemotherapy.
• • 3) New onset of respiratory symptoms; OR exacerbation of existing chronic respiratory symptoms (such as previously diagnosed chronic runny nose, seasonal allergies, chronic lung disease, etc.).
• • 4) Willing to sign an informed consent form, able to understand and willing to follow the study protocol.
• Exclusion Criteria:
• • Unwillingness to sign an informed consent form.